More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.94B
EPS
3.02
P/E ratio
13
Price to sales
2.44
Dividend yield
--
Beta
1.002215
Previous close
$33.76
Today's open
$33.78
Day's range
$32.87 - $34.01
52 week range
$25.90 - $43.49
show more
CEO
Jeffrey Dayno
Employees
293
Headquarters
Plymouth Meeting, PA
Exchange
NASDAQ Global Market
Shares outstanding
58723199
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth
Harmony Biosciences' Q3 earnings missed estimates as higher costs weighed on profits, while Wakix demand and pipeline progress supported its 2026 revenue outlook.
Zacks Investment Research • Nov 5, 2026

Harmony Biosciences Q3 Earnings Call Highlights
Harmony Biosciences NASDAQ: HRMY reported third-quarter net revenue of $269 million, up from $239 million a year earlier, as demand for its narcolepsy treatment WAKIX continued to grow. The company reiterated its full-year WAKIX net revenue guidance of $1 billion to $1.04 billion and said it expects to exceed $1 billion in annual WAKIX revenue for the first time.
MarketBeat • Nov 4, 2026

Harmony Biosciences Holdings, Inc. (HRMY) Q3 2026 Earnings Call Transcript
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 4, 2026

Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile
WAKIX ® Net Revenue in Q3 of $269 Million; Driven by Strong Demand with 400 Net Patient Adds in the Quarter; Reiterates Full Year Guidance of $1.0B to $1.04B
GlobeNewsWire • Nov 4, 2026

Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Lag Estimates
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.81 per share, missing the Zacks Consensus Estimate of $1 per share. This compares to earnings of $0.87 per share a year ago.
Zacks Investment Research • Nov 4, 2026

Harmony Biosciences Grapples With A Leadership Transition That Spooked Investors
Harmony Biosciences remains under pressure since the company announced its CEO transition. Will an upcoming narcolepsy drug change that?
Investors Business Daily • Oct 28, 2026

Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth
Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Oct 28, 2026

Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Investment Research • Oct 22, 2026

HRMY or ARGX: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
Zacks Investment Research • Oct 22, 2026

Revisiting Former Stock Picks Marriott, Logitech, Harmony Biosciences
Technical indicators have turned bullish for the Barron's Investor Circle stock picks.
Barrons • Oct 22, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Harmony Biosciences Holdings Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.